BRPI0811486A2 - Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2 - Google Patents

Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2

Info

Publication number
BRPI0811486A2
BRPI0811486A2 BRPI0811486-2A2A BRPI0811486A BRPI0811486A2 BR PI0811486 A2 BRPI0811486 A2 BR PI0811486A2 BR PI0811486 A BRPI0811486 A BR PI0811486A BR PI0811486 A2 BRPI0811486 A2 BR PI0811486A2
Authority
BR
Brazil
Prior art keywords
spla2
dislipidemia
inhibitors
cardiovascular disease
combination therapies
Prior art date
Application number
BRPI0811486-2A2A
Other languages
English (en)
Inventor
Joaquim Trias
Colin Hislop
Paul Truex
Bernardine Fraser
Debra Odinik
Scott Chadwick
Kenneth Gould
Patrick Eacho
Marian Mosior
Original Assignee
Anthera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthera Pharmaceuticals Inc filed Critical Anthera Pharmaceuticals Inc
Publication of BRPI0811486A2 publication Critical patent/BRPI0811486A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0811486-2A2A 2007-05-03 2008-05-02 Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2 BRPI0811486A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91591007P 2007-05-03 2007-05-03
US96959107P 2007-08-31 2007-08-31
US87486907A 2007-10-18 2007-10-18
PCT/US2008/062577 WO2008137803A1 (en) 2007-05-03 2008-05-02 Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies

Publications (1)

Publication Number Publication Date
BRPI0811486A2 true BRPI0811486A2 (pt) 2014-09-30

Family

ID=39943969

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811486-2A2A BRPI0811486A2 (pt) 2007-05-03 2008-05-02 Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2

Country Status (8)

Country Link
EP (1) EP2154958A4 (pt)
JP (1) JP2010526152A (pt)
CN (1) CN101742907A (pt)
AU (1) AU2008247451A1 (pt)
BR (1) BRPI0811486A2 (pt)
CA (1) CA2686157A1 (pt)
EA (1) EA200971020A1 (pt)
WO (1) WO2008137803A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081022A1 (en) * 2009-01-08 2010-07-15 Anthera Pharmaceuticals, Inc. Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia
RU2483707C1 (ru) * 2012-05-04 2013-06-10 Лира Талгатовна Гильмутдинова Способ санаторной терапии больных с метаболическим синдромом и артериальной гипертензией с применением сульфидных ванн
CN115040508A (zh) * 2022-07-28 2022-09-13 上海市同仁医院 吲哚-3-乙醛在制备新型抗肥胖活性制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
JP4459441B2 (ja) * 1998-05-01 2010-04-28 塩野義製薬株式会社 ｓＰＬＡ２阻害剤エステル
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
EP1309552A4 (en) * 2000-07-24 2005-07-20 Univ Queensland COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES
TWI314457B (pt) * 2001-03-19 2009-09-11 Shionogi & Co
WO2006034435A2 (en) * 2004-09-21 2006-03-30 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
WO2007056281A2 (en) * 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors

Also Published As

Publication number Publication date
EP2154958A4 (en) 2011-05-04
AU2008247451A1 (en) 2008-11-13
CA2686157A1 (en) 2008-11-13
EA200971020A1 (ru) 2010-10-29
JP2010526152A (ja) 2010-07-29
CN101742907A (zh) 2010-06-16
WO2008137803A1 (en) 2008-11-13
EP2154958A1 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
CY2019044I1 (el) Αναστολεις διυδροπυριδοφθαλαζινονης της πολυμερασης της πολυαδενοσφωσφορικης ριβοζης (parp)
CY2019009I1 (el) Αναστολεις πρωτεϊνικων κινασων
CY2017012I1 (el) Αναστολεις κινασης τυροσινης bruton
CY2017016I1 (el) Αναστολεις πρωτεασωματος
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
HK1152710A1 (en) Inhibitors of cytosolic phospholipase a2
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
NO345061B1 (no) Anvendelse av DPP-IV inhibitorer
BRPI1011129A2 (pt) métodos e compostos inibidores de janus cinase
BRPI0910668A2 (pt) inibidores de proteína quinases
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
BRPI0906735A2 (pt) Terapia de combinação que compreende inibidores de sglt e inibidores de dpp4
DK2379600T3 (da) Antistoffer mod tissue factor pathway inhibitor
BRPI0810086A2 (pt) inibidores de tirosina quinase de bruton
BRPI0715112A2 (pt) inibidores de undecaprenil pirofosfato sintase
BRPI0814797A2 (pt) Inibidores dna-pk
BRPI0911469A2 (pt) inibidores de gm-csf e il-17 para terapia
FI20065834A0 (fi) Iskulaite
BRPI0920681A2 (pt) inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17
ITFI20070288A1 (it) Inibitori delle deacetilasi istoniche
BRPI0920983A2 (pt) Combinações herbicidas contendo difluifenican e inibidores als
BRPI0811486A2 (pt) Tratamento de doença cardiovascular e dislipidemia usando inibidores de fosfolipase a2 secretória (spla2) e terapias de combinação com inibidor de spla2
BRPI0923192A2 (pt) tratamento de eventos cardiacos adversos maiores e síndrome coronária aguda empregando-se terapias de combinação de inibidores de fosfolipase a2 secretória (spla2) ou inibidor de spla2

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.